Price Alert

Biohaven Ltd. (BHVN)

NYSE: BHVN · Real-Time Price · USD

16.08

-0.13 (-0.80%)

At close: Sep 04, 2025, 3:59 PM

16.07

-0.06%

Pre-market: Sep 05, 2025, 06:01 AM EDT

-0.80% (1D)

Bid	15.71
Market Cap	1.7B
Revenue (ttm)	3.84M
Net Income (ttm)	-766.97M
EPS (ttm)	-7.46
PE Ratio (ttm)	-2.16
Forward PE	-2.74
Analyst	Buy

Ask	16.25
Volume	1,147,711
Avg. Volume (20D)	1,967,297.6
Open	16.06
Previous Close	16.21
Day's Range	15.69 - 16.27
52-Week Range	12.79 - 55.70
Beta	3.50

About BHVN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BHVN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BHVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Biohaven Ltd. is scheduled to release its earnings on Nov 11, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+6.34%

Biohaven shares are trading higher after the compa... Unlock content with Pro Subscription

1 month ago

+21.59%

Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.

News

2 days ago · businesswire.com

Biohaven Ltd. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BHVN

LOS ANGELES--(BUSINESS WIRE)--Biohaven Ltd. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BHVN.

1 week ago · seekingalpha.com

Biohaven: Despite Troriluzole Program Delay, FDA Review On Track For Q4 2025

Biohaven's troriluzole shows 50%-70% slowing of SCA disease progression, with FDA review now on track for Q4 2025 after a brief delay. FDA is no longer requiring an advisory committee meeting to revie...

2 weeks ago · fool.com

Why Biohaven Stock Zoomed More Than 6% Higher Today

On a very good Friday for the stock market, Biohaven's (BHVN 6.33%) performance was exceptional. The clinical-stage biotech's share price inflated by over 6% that trading session thanks to regulatory ...